Category: 3. Business

“The clinical benefits of Verida will fundamentally change my approach to cardiac imaging,” said Prof. Eliseo Vañó Galván, cardiovascular radiologist, Chairman of the CT & MR Department at Hospital Nuestra. Sra. Del Rosario, Madrid, Spain. “With more comprehensive insights in every cardiac CT, I plan to make spectral imaging routine for all patients – building toward a fully spectral CT department. We evaluated many systems, including photon-counting CT, but chose Philips because it delivers the precision we need in a streamlined, easy-to-use platform. The result is greater diagnostic confidence and the potential to reduce the need for invasive angiograms – not just in cardiology, but across other clinical areas as well [7].”

Verida reconstructs 145 images per second, so entire exams automatically appear in less than 30 seconds – 2× faster than before and enabling up to 270 exams every day [8]. Building on Philips’ proprietary Spectral Precise Image technology – a deep learning AI reconstruction engine combined with advanced spectral imaging – and its third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction optimized for AI, Verida is designed to deliver faster, more dose-efficient spectral reconstructions. This enables clinicians to access rich spectral information from a single scan.

“Combining the latest advances in our proven spectral CT technology with AI, our flagship Verida CT system is designed to set a new standard in superior image quality and accelerated scans which are fully embedded in the radiology workflow, all to help clinicians detect and characterize disease earlier, reduce variability in diagnoses, and support efficient treatment pathways – in a single scan,” said Dan Xu, Business Leader of CT at Philips. “While photon-counting CT adds complexity, is yet to move from the research arena into clinical practice, Philips spectral CT has been a clinical workhorse for more than a decade and delivers comparable or better clinical outcomes, standing up to the most demanding throughput and at significantly lower total cost of ownership”. 

Verida extends Philips’ software-defined CT approach, pairing AI-driven spectral precision to advance both clinical and operational outcomes. Built for high-demand environments, it streamlines workflows, reduces repeat scans, and delivers consistently sharp imaging across all care pathways.

Philips is debuting Verida at RSNA 2025, with availability in select markets beginning in 2026 [9].

Next-generation clinical AI on the Philips BlueSeal Horizon platform

 

Philips will bring next-generation clinical AI into everyday practice with the introduction of its new BlueSeal Horizon MR platform [1], simplifying workflows, enhancing diagnostic precision, and expanding access to advanced imaging. Key AI-powered innovations will include:
 

• SmartPlanning: Expanding to include cardiac imaging, this AI-driven feature will automate time-consuming planning steps. What once required multiple manual actions can now be completed in a single click, achieving automated planning in as little as 30 seconds. 
• Real-time Scan Preview: Powered by NVIDIA’s accelerated computing platform and Open Models (Segment and Generate), this innovation aims to enable faster 3D image reconstruction, denoising, and artifact reduction, so radiologists can preview scans, adjust image quality and speed parameters in real time, and optimize workflow efficiency for more timely diagnosis.
• SmartSpeed Precise: Dual AI technology will enable scans up to three times faster and images up to 80% sharper [4], helping clinicians capture more detail in less time. 
• SmartReading: This tool will integrate cloud-based AI reading and reporting tools directly on the MR system, specifically for neurology and oncology applications.

Together, these innovations will bring advanced clinical AI to the point of care, helping radiology teams achieve faster, sharper, and more consistent imaging results, supporting confident, first-time-right diagnosis. 

Specialty

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

In 2025, Indonesia and China marked the 75th anniversary of their diplomatic ties, highlighting how the relationship has matured into one of the Indo-Pacific’s most consequential. The commemoration signals not merely symbolism but the growing weight of a partnership that is expanding in trade, investment, and defence. At the same time, both states navigate cooperation alongside the imperative of maintaining autonomy.

For Beijing, Indonesia functions as a strategic partner and hub which an economic centre of gravity securing critical mineral supply chains for electric vehicles and renewable industries. Indonesia relations also serve as a geopolitical buffer on the southern flank of the South China Sea and key energy corridors to the Indian Ocean. Indonesia is seen as a pivotal Global South actor that can bolster China’s nonalignment narrative in platforms such as the United Nations, G20, and BRICS+.

Bilateral trade in 2024 reached US$135 billion, making China Indonesia’s largest trading partner. China is also the country’s second-largest foreign investor, investing in various sectors, including energy, smelters, and transportation infrastructure. During Prabowo Subianto’s state visit to Beijing in November 2024, both governments agreed on new investment commitments worth US$10 billion, covering mineral downstreaming, renewable energy, and digital infrastructure.

This indicates that Indonesia’s exports to China remain heavily reliant on critical minerals and commodities – with minimal technological value added. The reliance on Chinese inputs means that much of Indonesia’s industrial expansion, as stated in the government’s downstreaming policy, largely depends on the stability of Chinese supply chains.

Prabowo retains key policy instruments to recalibrate Indonesia’s position.

Significant Chinese investments in Indonesia’s critical minerals and renewable energy sectors have created path dependency, as much of the technological know-how Indonesia sought to acquire for its economic transformation is 75% controlled by Chinese companies. Since these projects rely on Chinese raw materials or midstream processing, this keeps Jakarta’s critical minerals industrial ecosystem tied to Beijing’s technological and financial orbit. Recent developments – including South Korea’s LG Energy Solution withdrawal and the likelihood of its replacement by a Chinese company – indicate that competitive pressure on Chinese firms remains limited and may even be narrowing. Still, this would not change the underlying dependence of Indonesia’s downstream industries on Chinese technology, capital, and supply chains.

Ironically, what the Indonesian government often touts as quick wins – high-speed rail, industrial parks, battery factories – are merely the local face of a global chain controlled by Beijing. In this framework, Indonesia’s economic sovereignty is not a matter of ownership, but rather the extent to which it can break free from Beijing’s orbit without incurring excessive political and social costs.

In this overall strategy, it is clear that Beijing has chosen a path of “tying up” Indonesia rather than putting it under its sphere of influence. Instead of formal alliances, Beijing relies on these long-term linkages to ensure that Indonesia does not drift too far away from its orbit. As long as strategic minerals and downstream industries in Indonesia remain based on Chinese technology, and as long as Indonesia remains engaged with the Shanghai Cooperation Organisation (SCO) – signified by Indonesia’s first-ever attendance at this year’s SCO leaders’ summit in Tianjin – Beijing does not need to open a new imprint in Southeast Asia.

For Beijing, Indonesia is likely to remain closely tied to China so long as the costs of reducing Jakarta’s economic and technological dependence outweigh the benefits of diversification. However, this trajectory is not predetermined. While President Prabowo Subianto has signalled that economic cooperation with China will continue, Indonesia is inviting other countries such as Australia and the United States to invest in Indonesia’s critical minerals industry, to ensure that the supply chain is not completely dependent on investment from China. However, so far this diversification strategy remains symbolic, since most projects still depend on Chinese technology and financing.

Nonetheless, Prabowo retains key policy instruments to recalibrate Indonesia’s position – tightening technology-transfer requirements, widening capital sources beyond EPC-driven projects, and reinforcing ASEAN-led frameworks that preserve open regional norms.

The Indonesian government may propose that technology transfer should be an integral part of future critical minerals and renewable energy investment from China. It should be subject to regular, independent evaluation and strict enforcement to ensure that Chinese projects generate not only physical infrastructure but also genuine skill diffusion among Indonesian engineers, data scientists, and other professionals. Jakarta can institutionalise this by conditioning investment approvals on clear R&D collaboration benchmarks and vocational training commitments with Chinese firms so that technological gains convert into domestic capability. Rather than deterring investment, such measures would enhance its credibility and long-term sustainability.

Whether Indonesia remains tied up or gradually redefines its trajectory in its economic relations with China will depend on how these instruments are used.

NeurologyLive® first published this article. This version has been lightly edited.

Recently reported data from the phase 2 portion of the KYSA-6 trial (NCT06193889) show that treatment with investigational KYV-101 (Kyverna Therapeutics), a CD19 chimeric antigen receptor (CAR) T-cell therapy, led to clinically meaningful responses in efficacy end points for patients with generalized myasthenia gravis (gMG). Overall, the data reinforce the potential of this novel therapeutic, which continues to be studied in the ongoing phase 3 portion of KYSA-6.^1,2

The trial, which was previously a phase 2 study but amended to phase 2/3, included patients aged 18 to 75 years with gMG, a history of acetylcholine receptor or muscle-specific kinase autoantibodies, and a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of at least 6. Presented at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, held October 29 to November 1, 2025, in San Francisco, California, the presentation featured 6 patients with moderate to severe gMG and an average disease duration of 5.3 years (range, 1.7-13.3) who were treated with a single dose of 1×108 KYV-101 CAR T cells.

At data cutoff, or up to 36 weeks, the 6 patients achieved clinically meaningful, robust, rapid, and sustained reductions in MG-ADL and Quantitative Myasthenia Gravis (QMG) scores, the dual primary outcomes, regardless of prior biologic exposure. Specifically, treated patients demonstrated mean reductions of –8.0 points on MG-ADL and –7.7 points on QMG at 24 weeks, with effects observed as early as 2 weeks post infusion.

“These unprecedented results validate our phase 3 trial design and underscore KYV-101’s potential to deliver durable, drug-free, disease-free remission by targeting the disease at its source through deep B-cell depletion,” Naji Gehchan, MD, MSc, MBA, chief medical and development officer at Kyverna, told NeurologyLive. “We’re eager to continue this progress to help address unmet needs for patients living with generalized myasthenia gravis.”

Efficacy data showed that all patients achieved at least a 3-point reduction in both MG-ADL and QMG, in addition to achieving a clinically meaningful response on Myasthenia Gravis Composite (MGC) scores. At 12 weeks, patients showed a mean reduction of –12 points on their MGC score, all while being free of nonsteroidal immunosuppressants, high-dose steroids, and neonatal Fc receptor and complement inhibitors.

In terms of safety, KYV-101 was shown to be well tolerated, with no new safety signals and 1 case of a serious adverse event (grade 4 neutropenia), which improved with standard supportive care and was downgraded to grade 1 at data cutoff. Notably, patients on the CAR T-cell therapy did not experience any high-grade cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome events throughout the study period.

Gehchan added, “While there are many approved therapies and new therapies under development for gMG, none have been able to address the underlying disease on a mechanistic level. With KYV-101, we are taking a novel, upstream approach to directly target the disease source by tapping into the patient’s own immune cells to fight disease.

“As an investigational CAR T-cell therapy, KYV-101 directly targets the disease source by deeply depleting the autoreactive B cells in tissues. In addition, KYV-101 has been shown to have a positive impact on a broader set of immune cell types and, in particular, regulatory T cells, which are essential for keeping the immune system in check.”

KYV-101, which is also being studied for other diseases, including progressive multiple sclerosis, received a regenerative medicine advanced therapy designation from the FDA in August 2024, further recognizing it as a promising treatment for gMG. The CAR in KYV-101 was designed by the National Institutes of Health to improve tolerability and was tested in a phase 1 trial (NCT02659943) in oncology with results published in Nature in 2020.³

The first-in-human study enrolled 20 patients with B-cell lymphoma and was designed primarily to evaluate safety and feasibility, with secondary assessments focused on blood levels, antilymphoma activity, the potential for second infusions, and immunogenicity. At the time known as Hu19-CD828Z T-cell therapy, KYV-101 met all of its study objectives. Patients treated with the therapy showed lower cytokine levels compared with those who received FMC63-28Z T cells, a finding investigators suggested could account for the reduced neurologic toxicity observed with the agent.

In early 2024, Kyverna reported the first individual treatments with KYV-101 in 2 patients with progressive multiple sclerosis. The therapy was well tolerated in the short term, showing CAR T-cell expansion in the cerebrospinal fluid without neurotoxicity and a reduction in intrathecal antibody production in 1 patient. Although both had previously received ocrelizumab, circulating B cells were detected only in patient 1, whose remaining B-cell population was depleted by day 2 and remained absent through day 100. Patient 1 also experienced a drop in oligoclonal bands (OCBs) from 13 to 6 by day 64, while patient 2 showed no changes in OCBs or intrathecal immunoglobulin levels.⁴

Gehchan concluded, “We believe KYV-101’s clinical profile provides us with an advantage. We anticipate a large effect size based on the first patients in the compassionate use pathway that has now been confirmed in this interim phase 2 readout. This enables us to have a more efficient study design with only about 60 patients to be randomized between standard of care and KYV-101. We are also including important [pharmokinetic] and [pharmacodynamic] end points like B-cell depletion and looking at effects on immune cell populations to help support our mechanistic approach that complements the other outcome assessments.”

References
1. Kyverna Therapeutics announces positive interim phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis at AANEM 2025. News release. Kyverna Therapeutics. October 29, 2025. Accessed November 19, 2025. https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-announces-positive-interim-phase-2-data
2. Muppidi S, Hunter MC, Hoffmann S, et al. Update on the phase 2 part of KYSA-6, an open-label, single-arm, multicenter study of KYV-101, a fully human CD19 chimeric antigen receptor T-cell therapy in generalized myasthenia gravis. Presented at: 2025 AANEM Annual Meeting. October 29-November 1, 2025; San Francisco, CA. Abstract 106.
3. Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Med. 2020;26(2):270-280. doi:10.1038/s41591-019-0737-3
4. Fischbach F, Richter J, Pfeffer LK, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550-558.e2. doi:10.1016/j.medj.2024.03.002

Founded in 1869, Goldman Sachs is the world’s second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue. The Wall Street white-glove giant offers financing, advisory services, risk distribution, and hedging for the firm’s institutional and corporate clients. We review the firm’s Conviction List of top stock ideas monthly, seeking companies with the highest dividends and the safest profiles. With the year winding down, we decided to review the current list of high-yielding stocks that can provide secure, reliable passive income.

• December could prove to be another volatile month, so growth and income investors may want to reset their portfolios.

• Goldman Sachs Conviction List: the highest-yielding stocks have huge total return potential.

• The Conviction List dividend stocks may get a nice boost if the Fed lowers rates at its December meeting.

• Some investors get rich while others struggle because they never learned there are two completely different strategies to building wealth. Don’t make the same mistake, learn about both here.

The Goldman Sachs Conviction List is a curated list of stocks that the firm’s research team believes have a high likelihood of outperforming the market. It’s a tool for investors to identify stocks with strong growth potential, frequently updated to reflect changes in market conditions and company performance. The list aims to identify stocks where Goldman Sachs analysts have the “highest level of conviction” in their outperformance. We screened the list for dividend-paying stocks likely to receive a significant tailwind as the Federal Reserve continues on a rate-cutting cycle, and five are outstanding stocks with big, reliable dividends and strong total return potential.

Goldman Sachs is the acknowledged leader in the investment landscape on Wall Street and worldwide. The firm’s top-notch research department continues to provide institutional and high-net-worth clients with the best ideas across the investment spectrum. It is likely to continue doing so for years.

This quality REIT offers steady, reliable income, a portfolio of outstanding properties, and a rich 4.40% dividend. Brixmor Property Group (NYSE: BRX) is an internally managed real estate investment trust (REIT). The Company conducts its operations primarily through Brixmor Operating Partnership LP and subsidiaries (collectively, the Operating Partnership).

The Company owns and operates open-air retail portfolios by gross leasable area (GLA) in the United States, comprised primarily of community and neighborhood shopping centers. The Company’s portfolio consists of approximately 360 retail centers (the Portfolio) totaling over 64 million square feet of GLA.

Brixmor Property Groups’ projects include:

• Dickson City Crossings

• East Port Plaza

• Fox Run

• Gateway Plaza

• Old Bridge Gateway

• Pointe Orlando

• Shops at Palm Lakes

• Stewart Plaza

• Tinley Park Plaza

• Tyrone Gardens

• Vail Ranch Center

• Venice Village

• Village at Mira Mesa

• Westminster City Center

The Company’s national portfolio is primarily located within established trade areas in the top 50 Core-Based Statistical Areas (CBSAs) in the United States.

Goldman Sachs has a $32 target price for the stock, representing 22% upside.

Duke Energy is an American electric power and natural gas holding company headquartered in Charlotte, North Carolina. It is located in a growing part of the country and pays a hefty 3.44% dividend. Duke Energy Corporation (NYSE: DUK) and its subsidiaries operate as energy companies in the United States.

It operates through two segments:

The EU&I segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, and the Midwest.

To develop electricity, Duke Energy uses the following:

• Coal

• Hydroelectric

• Natural gas

• Oil

• Solar and wind sources

• Renewables

• Nuclear fuel

This segment also sells electricity to municipalities, electric cooperative utilities, and load-serving entities.

The GU&I segment distributes natural gas to

The segment also invests in pipeline transmission projects, renewable natural gas projects, and natural gas storage facilities.

Goldman Sachs’ price target for the company is $138, representing an 11% gain from current trading levels.

With Christmas right around the corner, this is an excellent idea for growth and income investors with a solid 2.91% dividend. The Hershey Company (NYSE: HSY) is a snacks company.

The Company’s segments include:

The North America Confectionery segment is responsible for its traditional chocolate and non-chocolate confectionery market position in the United States and Canada.

This includes its business in:

• Chocolate and non-chocolate confectionery

• Gum and refreshment products

• Protein bars

• Spreads

• Snack bites and mixes

• Pantry and food service lines

This segment also includes its retail operations.

The North America Salty Snacks segment is responsible for its salty snacking products in the United States. This includes ready-to-eat popcorn, baked, trans-fat-free snacks, pretzels, and other snacks.

The Company’s portfolio includes chocolate and confectionery brands such as:

The Goldman Sachs target price for the stock is $220, representing a massive 30% gain for investors.

This is a way to play the energy sector on the services side, and the company pays shareholders a massive 5.15% dividend. Kodiak Gas Services, Inc. (NYSE: KGS) is a contract compression service provider in the United States, serving as a vital link in the infrastructure that enables the production, transportation, and distribution of natural gas and oil.

The Company’s segments include Contract Services and Other Services.

The Contract Services segment comprises operating Company-owned and customer-owned compression, gas treating, and cooling infrastructure that enable the production, gathering, processing, and transportation of natural gas and oil.

The Other Services segment consists of a broad range of services to support the needs of its customers, including:

• Station construction

• Customer-owned compression maintenance and overhaul,

• Freight and crane charges

• Parts sales

• Ancillary time and material-based offerings

Kodiak Gas Services offers its services to:

• Oil and gas producers

• Midstream customers in high-volume gas gathering systems

• Processing facilities

• Multi-well gas lift applications

• Natural gas transmission systems

Hitting the Goldman Sachs $42 target would be almost a 14% gain.

This is one of the safest ways for investors to play the energy sector, as refining capacity has shrunk while supply has increased. Valero Energy Corporation (NYSE: VLO), through its subsidiaries, is a multinational manufacturer and marketer of petroleum-based and low-carbon liquid transportation fuels, as well as petrochemical products, and pays a dependable 2.56% dividend.

The Company sells its products primarily in:

• The United States

• Canada

• The United Kingdom

• Ireland

• Latin America

Valero operates through three segments:

• Refining

• Renewable Diesel

• Ethanol

The Refining segment encompasses the operations of its petroleum refineries, the associated marketing activities for its refined petroleum products, and the logistics assets that support these operations.

The Renewable Diesel segment encompasses Diamond Green Diesel (DGD) and its associated activities, including marketing renewable diesel and renewable naphtha.

The Ethanol segment includes the operations of its ethanol plants and the associated activities involved in marketing its ethanol and co-products.

Valero Corporation owns over 15 petroleum refineries located in the United States, Canada, and the United Kingdom.

Goldman Sachs has set a target price of $197 for the stock, a gain of 16%

The fact is there are two totally different investment paths you can take right now. And while either can make you some money, choosing the right one at the right time can mean the difference between just getting by and getting truly rich. Most people don’t even realize the difference, and that mistake can be devastating for your portfolio. Whether you’re investing $1,000, or $1,000,000 today, learn the difference and put yourself on the right path. See the report.

• Zoomd Technologies Ltd. reported improved third quarter profitability, with net income rising to US$3.8 million despite a 3% revenue decrease due to a one-time boost in the prior year, and announced a new global partnership with E2 Quadrat Communication aimed at expanding client acquisition ahead of the 2026 World Cup.

• Alongside record cash flow and no long-term debt, Zoomd’s approach now includes seeking acquisitions and building strategic alliances to broaden its customer base and strengthen technological capabilities.

• We’ll examine how Zoomd’s focus on operational efficiency and global partnerships could shape its investment story going forward.

Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

For those considering Zoomd Technologies, the story is increasingly about disciplined execution and how new partnerships or M&A could speed up growth in a competitive sector. The recent news of improved profits, strong cash flow, and no long-term debt reinforce the impression of operational control, even as short-term catalysts shift. The collaboration with E2 Quadrat, timed ahead of major sporting events like the 2026 World Cup, directly addresses one key catalyst: faster client acquisition in high-potential markets. Importantly, management’s newly reiterated focus on acquisitions could boost earnings or reshape the company’s risk profile if any deals are pursued soon, a factor not recognized in earlier fair value estimates or risk assessments. Still, rapid expansion comes with the risk of execution missteps, especially if new initiatives strain resources or slow the profitable momentum seen in the last year. However, investors should note the ongoing risk that acquisitions or rapid client onboarding strain current efficiencies.

Despite retreating, Zoomd Technologies’ shares might still be trading above their fair value and there could be some more downside. Discover how much.

Most recent fair value estimates from 10 Simply Wall St Community members range widely, from US$1.09 to US$19.28 per share. While some see extreme upside, others remain more cautious. The possible impact of upcoming acquisitions and sector competition is a key reason why opinions diverge so much, making it essential to weigh several viewpoints as you consider Zoomd’s next phase.

Explore 10 other fair value estimates on Zoomd Technologies – why the stock might be worth 23% less than the current price!

Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.

• A great starting point for your Zoomd Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.

• Our free Zoomd Technologies research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Zoomd Technologies’ overall financial health at a glance.

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZOMD.V.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com